We will absolutely need to continue our endeavors to evaluate reliable predictive biomarkers for both targeted drugs and immunotherapeutic agents to achieve a truly personalized melanoma therapy with the maximal clinical benefit.
Kevin B. Kim, MD
Advertisement
Articles by Kevin B. Kim, MD
Advertisement
Latest Updated Articles
- The Past, Present, and Future of Melanoma Therapy
May 15th 2013
Advertisement
Advertisement
Trending on CancerNetwork
1
Dose Modification Strategies in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
2
Utilizing AI Algorithms to Inform Breast Cancer Chemoprevention Strategies
3
I-DXd Earns FDA Priority Review in Extensive-Stage Small Cell Lung Cancer
4
FDA Receives sBLA for Zenocutuzumab in Advanced NRG1+ Cholangiocarcinoma
5